

Retinal toxicity after repeated intravitreal carboplatin injection into rabbit eyes

Pavel Pochop^a, Denisa Darsova^a, Jiri Uhlík^b, Jan Lestak^f, Jiri Kukacka^c, Daniela Kodetova^d, Eva Klappkova^c, Josef Malis^e,
Ludek Vajner^b

Background. The aim of this study was to assess retinal toxicity in a rabbit model after carboplatin delivered as repeated transcorneal intravitreal injection, in order to determine the highest possible safe dose for use in human retinoblastoma "seeding" tumor chemotherapy.

Methods and Results. We used six albino rabbits in an *in vivo* experiment and injected 0.008 mg of carboplatin intravitreally (iv) 4 times at two-week intervals. 0.08 mL saline was injected into the left eye. We recorded electroretinograms (ERGs) before the first carboplatin injection and after the fourth injection. Platinum concentration was measured 1 h after the fifth additional injection. We found reduced dark-adapted b-wave amplitudes and, light-adapted b-wave and a-wave amplitudes. The differences between right and left eyes was significant but we found no histopathologic retinal changes.

Conclusions. 0.008 mg of carboplatin is probably the highest possible safe dose for the treatment of retinoblastoma patients. Questionable is direct extrapolation of retinal toxicity from the rabbit eye model to the human eye.

Key words: carboplatin concentration, electroretinogram, intravitreal seeding, local treatment, rabbit, retinoblastoma

Received: July 13, 2012; Accepted: November 29, 2012; Available online: December 10, 2012
<http://dx.doi.org/10.5507/bp.2012.106>

^aDepartment of Ophthalmology for Children and Adults, 2nd Faculty of Medicine, Charles University in Prague, Czech Republic

^bDepartment of Histology and Embryology, 2nd Faculty of Medicine, Charles University in Prague

^cDepartment of Clinical Biochemistry and Pathobiochemistry, 2nd Faculty of Medicine, Charles University in Prague

^dDepartment of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University in Prague

^eDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague

^fDepartment of Ophthalmology, Clinic of Jan Lestak, Prague

Corresponding author: Pavel Pochop, e-mail: pavel.pochop@gmail.com

INTRODUCTION

Retinoblastoma is a childhood cancer arising from immature retinal cells in one or both eyes. Chemotherapeutics are used in treatment but vitreous seeding is a serious limiting factor in retinoblastoma therapy. Various modalities to increase intravitreal concentrations of chemotherapeutics have been tested, for example, coulomb-controlled iontophoresis¹, peribulbar administration², cryotherapy one day before intravenous carboplatin with or without cyclosporine³ etc. Some are too complex for clinical practice or vitreous concentrations of chemotherapeutic do not reach effective levels and are unstable¹. Another described treatment is intravitreal transscleral injection of chemotherapeutic agent^{4,5}. No serious complications have been found to date but tumor dissemination in human retinoblastoma was demonstrated by subsequent fine needle biopsy or pars plana vitrectomy⁶. Hence, some physicians used a more difficult approach through the limbus, anterior chamber and peripheral iris for fine needle aspiration biopsy to avoid seeding tumor cells into orbital tissues^{7,9}. This approach was also used in this experiment. We assessed possible retinal changes after transcorneal intravitreal carboplatin injection which would preclude its use in clinical practice. We chose the rabbit and we selected a dose of 0.008 mg according to

previously published data^{10,11}, where a dose of 0.001 mg induced no changes on electroretinograms (ERGs) and a dose of 0.01 mg evoked significant alterations. The dose we chose was near the upper limit in order to achieve the most effective concentration.

MATERIALS AND METHODS

Animals and drug delivery

After approval by the Faculty Committee on animal welfare, New Zealand albino male specified pathogen-free (SPF) healthy rabbits (Anlab, Prague, Czech Republic) (n = 6) received a 0.008 mg dose of carboplatin dissolved in 0.08 mL of saline by unilateral transcorneal intravitreal injection into the right eye. The same volume of saline was injected into the left eye of each animal as a sham control. The same procedure was carried out 4 times at two-week intervals. Rabbits were kept under standard laboratory conditions. Ambient temperature was 20–24 °C, and relative air humidity ranged from 55–60%. They were anesthetized with a mixture of ketamine hydrochloride (50 mg/kg, Narketan 10 a.u.v. inj, Vétoquinol, Lure Cedex, France) and xylazine hydrochloride (5 mg/kg, Rometar 2% a.u.v. inj, Spofa, Prague, Czech Republic) given intramuscularly (im) before the intervention. Topical oxybu-

procaine anesthetic eyedrops (0.4%, Benoxi gtt., Unimed Pharma, Bratislava, Slovakia) were instilled into the conjunctival sacs and the eyelids were fixed with a sterile speculum. A total of 3 mL of 1% povidoneiodine solution (10% Betadine, EGIS Pharmaceuticals Ltd., Budapest, Hungary) was used for disinfection. Two months after the first injection of carboplatin, all rabbits were euthanatized by exsanguination via the carotid arteries under general anaesthesia and their eyes were processed for histopathologic examination.

Electroretinograms (ERGs) were recorded before the first and 2 weeks after the fourth injections. Electroretinographic readings consisted of a series of intensities presented under dark and light-adapted conditions according to the ISCEV protocol. Pupillary mydriasis was induced by instillation of one drop of tropicamide 0.5% (Mydrum, Chauvin Ankerpharm GmbH, Germany). After 30 min of dark adaptation, ERGs were recorded simultaneously with a skin electrode and direct corneal ERG-jet contact lens electrode¹². The skin electrode was placed 1 cm behind the lower lid (Fig. 1). A skin electrode on the forehead served as a ground. Stimulation and recording of the ERGs were performed with the RETIscan system (Roland Consult, Brandenburg, Germany). The rod (scotopic) ERG was recorded with a white flash at an intensity of 0.01 cd.s.m⁻² and for maximal scotopic answer an intensity of 3.0 cd/m².s. The cone (photopic) ERG was recorded with the same stimuli intensities (3.0 cd/m².s) and background illumination of 30 cd/m². Statistical analysis was done using the software Statistica 9.1 WAN (StatSoft, Tulsa, USA). Data were compared using a t-test. $P \leq 0.05$ was considered statistically significant.

Carboplatin concentration measurement

To measure the platinum concentration, an additional, i.e. fifth, dose of the carboplatin was injected into the right eyes after the second ERG. Samples of vitreous humour were collected one hour later to verify the concentration of carboplatin in the vitreous cavity. Electrothermal

atomic absorption spectrometry (ET-AAS) was employed to analyze the total platinum concentrations in vitreous humour after the last administration as a suitable method for carboplatin concentration determination. ET-AAS determines total Pt in fluids or tissues, including any forms of the drug subject to hydrolytic action and subsequently inactivated by irreversible binding to protein and thus rendered inactive and not cytotoxic. The platinum concentration was measured by graphite-furnace atomic absorption spectrophotometry with Zeeman background correction (Varian 220 Z, Australia). 100 µL of vitreous humour was diluted 1:14 with a solution containing Triton X-100 (0.2 vol %), antifoam A (0.2 vol %), and deionized water. A programmable sample dispenser piped the samples and calibration standard into the furnace. Platinum determination was carried out by the standard additions method. The highest possible concentrations of carboplatin immediately after its administration were calculated according to the globe diameter.

RESULTS

All animals were followed up during the experimental period by a veterinarian. No treatment-induced weight changes were found as a sign of the general toxicity of carboplatin. One animal perished suddenly during general anesthesia before the fourth carboplatin administration. Its gross dissection showed no other cause of death. We found no structural changes on histopathologic examination of the eyes.

Statistically significant reductions in the dark-adapted b-wave (ra - b) amplitudes and in the maximal scotopic answer (msa - b) amplitudes and also elevation of cone answer (Fig. 2, Tables 1 and 2) were found in carboplatin treated eyes. We also found statistically significant changes in ra - b, msa - a, msa - b and ca - b waves in the ERGs records of control eyes (Tables 1 and 3). There were no structural changes on histopathologic examination. The measured average platinum concentration one hour after additional injection was 1349 µg/L. The calculated highest possible average concentration of carboplatin according to the globe diameters was 8422 µg/L immediately after application of 0.008 mg of carboplatin.

DISCUSSION

We found significant changes in the ERG records after repeated injection of 0.008 mg of carboplatin into right eyes. Similar but more serious changes were found after single intraocular injection of higher dose (more than 0.01 mg) of carboplatin¹⁰. Repeated intraocular injection of 0.05 mg of carboplatin resulted in serious ERG changes and also structural changes – chorioretinal atrophy found by histopathologic examination¹¹. Similar ERGs changes (elevation in ca - a) were also recorded after lead exposure¹³.

Due to the effect of carboplatin on right eyes, changes in ERG records were significantly different to changes




Fig. 1. Corneal ERG-jet contact lens electrode and skin electrode behind lower lid.




Fig. 2. ERG - Rabbit No. 932038 - Right eye after administration of the carboplatin.

Table 1. ERGs before and after administration of carboplatin (right eyes) and saline (left eyes).

Rabbit No.	ra - b (µV)	msa - a (µV)	msa - b (µV)	ca - a (µV)	ca - b (µV)	category
932038	132	108	230	5	87	right b
931018	91	105	114	2.8	81.2	right b
932012	132	139	233	5.8	59	right b
902035	52.7	87	145	0.8	25.2	right b
932337	94	84.5	212	1.4	48.5	right b
932038	29.8	68.2	32.6	20	23.4	right a
931018	6.79	93.8	30.5	29.8	9.7	right a
932012	3.32	117	88.7	32	18.8	right a
902035	9.42	69.8	25.8	30.8	2.32	right a
932337	1	62	33.2	11.8	13	right a
932038	99	85	199	1	76	left b
931018	73	73.5	96	5.2	65.7	left b
932012	72.6	90	140	4.68	64	left b
902035	69	78	158	3.34	46.5	left b
932337	72	40	130	0.9	46.6	left b
932038	64.6	50.2	103	13.1	44.8	left a
931018	34.1	24.3	52.5	2.79	27.5	left a
932012	35.2	30.5	70.1	2.7	39.9	left a
902035	29.5	72.3	81.3	6.51	34.2	left a
932337	23.7	21.5	47.5	6.77	37.1	left a

Legend:

Rabbit No. = rabbit number

ra - b = rod answer, wave b

msa = maximal scotopic answer

ca = cone answer

right b = right eye before administration

right a = right eye after administration

left b = left eye before administration

left a = left eye after administration

Table 2. Right eyes before and after administration of carboplatin.

	mean right b	mean right a	SD right b	SD right a	<i>P</i>
ra - b	100.3400	9.90600	33.17270	11.14920	0.000415*
msa - a	104.7000	82.16000	21.84491	22.93138	0.150185***
msa - b	186.8000	42.16000	54.04350	26.17848	0.000657*
ca - a	3.1600	24.88000	2.18815	8.72995	0.000649*
ca - b	60.1800	13.44400	25.11259	8.15118	0.004188*

**P*<0.01


*** neglectable

Table 3. Left eyes before and after administration of saline.

	mean left b	mean left a	SD left b	SD left a	<i>P</i>
ra - b	77.1200	37.30000	12.33175	15.59920	0.002062*
msa - a	73.3000	39.76000	19.66469	21.36605	0.032478**
msa - b	144.6000	70.88000	37.86555	22.50182	0.005685*
ca - a	3.0240	6.37400	2.01154	4.23550	0.148806***
ca - b	59.7600	36.70000	12.90360	6.45949	0.007258*

P*<0.01*P*<0.05

*** neglectable

**Fig. 3.** Mean values of ERG before and after administration of carboplatin.

in ERGs of left eyes (Fig 3). Changes in ERGs, which were recorded in left eyes, may be caused by high intraocular pressure and transient ischemia during injection of saline¹⁴.

All changes are probably reversible and depend on the period of intraocular pressure increase¹⁵ during intravitreal injection of carboplatin and saline. Recovery of visual functions was expected as we found no structural changes

on histopathologic examinations but an extended period of time for recovery was probably necessary¹⁶.

CONCLUSION

Intravitreal delivery of 0.008 mg of carboplatin resulted in damage to retinal function but not structure. Thus, the changes are probably transient. The dose of carboplatin we used is probably the highest possible for the treatment of retinoblastoma patients. Questionable is, of course, the direct extrapolation of retinal toxicity from the rabbit eye model to the human eye.

ACKNOWLEDGEMENT

Authorship contributions: PP, DD: literature search; PP: manuscript writing and study design; All authors: data collection; JL, JU, LV: data analysis; JL, JU, LV, DK: data interpretation; JU, LV: statistical analysis, PP, DD: figures; PP: final approval.

Conflict of interest statement: None declared.

REFERENCES

- Hayden BC, Jockovich ME, Murray TG, Voigt M, Milne P, Kralinger M, Feuer WJ, Hernandez E, Parel JM. Pharmacokinetics of systemic versus focal carboplatin chemotherapy in rabbit eyes: possible implication in the treatment of retinoblastoma. *Invest Ophthalmol Vis Sci* 2004;45:3644-9.
- Mendelsohn ME, Abramson DH, Madlen T, Tong W, Tran HT, Dukel U. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. *Arch Ophthalmol* 1998;116:1209-12.
- Wilson TW, Chan HSL, Moselhy GM, Heydt DD Jr, Frey CM, Gallie BL. Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. *Arch Ophthalmol* 1996;114:1390-5.
- Kaneko A, Suzuki S. Eye-Preservation Treatment of Retinoblastoma with Vitreous Seeding. *Jpn J Clin Oncol* 2003;33:601-7.
- Velez G, Yuan P, Sung C, Tansey G, Reed GF, Chan CC, Nussenblatt RB, Robinson MR. Pharmacokinetics and Toxicity of Intravitreal Chemotherapy for Primary Intraocular Lymphoma. *Arch Ophthalmol* 2001;119:1518-24.
- Shield JA, Shields CL. Intraocular Tumors: A Text and Atlas. Philadelphia, Pa: WB Saunders Co. 1992:305-91.
- Pochop P, Darsova D, Kukacka J, Tesfaye H, Vajner L, Uhlik J, Kodetova D, Malis J, Dotrelova D. Intravitreal carboplatin concentration and area under concentration versus time curve after intravitreal and periocular delivery. *Eur J Ophthalmol* 2010; 20:745-51.
- Cohen VM, Shields CL, Fruta M, Shields JA. Vitreous Seeding From Retinal Astrocytoma in Three Cases. *Retina* 2008;28:884-8.
- Karcioglu ZA. Fine Needle Aspiration Biopsy (FNAB) for Retinoblastoma. *Retina* 2002;22:707-10.
- Harbour JW, Murray TG, Hamasaki D, Ciciarelli N, Hernández E, Smith B, Windle J, O'Brien JM. Local carboplatin therapy in transgenic murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1996; 37:1892-8.
- Pochop P, Darsova D, Uhlik J, Lestak J, Kukacka J, Kodetova D, Vajner J, Malis J, Dotrelova D. Evaluation of retinal toxicity of carboplatin after repeated transcorneal intravitreal injection. In: Monduzzi editor. *Proceedings of the 8th International Symposium on Ocular Pharmacology and Therapeutics – ISOPT, Rome, Italy, 2009 3-6 December; Bologna; 2009. p. 155-161.*
- Pradue MT, Hejny C, Gilbert JA, Phillips MJ, Geroski DH, Edelhauser HF. Retinal function after subconjunctival injection of carboplatin in fibrin sealant. *Retina* 2004; 24:776-82.
- Rothenberg SJ, Schnaas L, Salgado-Valladares M, Casanueva E, Geller AM, Hudnell HK, Fox DA. Increased ERG a- and b-Wave Amplitudes in 7- to 10-Year-Old Children Resulting from Prenatal Lead Exposure. *Invest. Ophthalmol Vis Sci* 2002;43:2036-44.
- Kremmer S, Tolksdorf-Kremmer A, Stodtmeister R. Simultaneous registration of VECP and pattern ERG during artificially raised intraocular pressure. *Ophthalmologica* 1995;209:233-41.
- Zhao H, Ai Y, Niu C, Guan W, Li X, Qin L. Research on Influences of Transient High IOP during LASIK on Retinal Functions and Ultrastructure. *J Ophthalmol*. 2009;2009:230528.
- Polito A, Cereda M, Romanelli F, Pertile G. Macular translocation with 360 degrees retinotomy for management of retinal pigment epithelial tear: long-term results. *Br J Ophthalmol* 2010;95:74-8.